Anthrax Vax Test OK for Kids

A presidential bioethics commission lays out the framework for testing the anthrax vaccine in children.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

CDC, JUDY SCHMIDTIf the risks are low, researchers could be permitted to study the anthrax vaccine in children, according to a 146-page report released today (March 19) by the Presidential Commission for the Study of Bioethical Issues. The commission was tasked with investigating the issue in the fall of 2011 after the National Biodefense Science Board (NBSB) recommended trial of the anthrax vaccine in children.

“This was one of the most difficult ethical reviews that any bioethics commission has ever conducted,” the commission's chair, Amy Gutmann, president of the University of Pennsylvania, told ScienceInsider. On one hand, understanding appropriate usage and dosage of such a vaccine in children is critical for an effective response in the face of a bioterrorist threat. On the other hand, the study would likely expose children to certain risks and may offer no benefit to trial participants.

In weighing these considerations, the commission emphasized that the risks, such as soreness around an injection site, should be “minimal.” Such risks could be demonstrated in a study of young adults, such as those in the US military who have already received the vaccine—made from an inactivated protein ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies